Yahoo Finance

Viewpoint Molecular Targeting(TM) Chief Scientific Officer, Dr. Michael Schultz, Discusses the Promise of Image-Guided 212Pb Alpha-Particle Radiopharmaceutical Therapies for ...

CORALVILLE, IA / ACCESSWIRE / June 15, 2021 /Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology ...
MediaPost

Viewpoint Snaps Up Unicast

Viewpoint, Inc., a technology vendor and rich media content provider, yesterday announced it would acquire Unicast Communications, a rich media ad serving company, for $7.4 million. The deal is ...
Yahoo Finance

Viewpoint Molecular Targeting(R) Appoints Thijs Spoor as Chief Executive Officer

Established leader with nearly 30 years of combined executive, broad management and capital markets expertise across healthcare and medical device industries CORALVILLE, IA / ACCESSWIRE / February 22, ...
Business Wire

Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT

RICHLAND, Wash. & CORALVILLE, Iowa--(BUSINESS WIRE)--Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, and Viewpoint Molecular Targeting, Inc., a ...
Nasdaq

Viewpoint Molecular Targeting Announces Transformational Merger

CORALVILLE, IA / ACCESSWIRE / September 29, 2022 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle ...
Business Wire

Visus Therapeutics Expands Ophthalmic Drug Development Portfolio With Acquisition of ViewPoint Therapeutics’ Assets

SEATTLE--(BUSINESS WIRE)--Visus Therapeutics Inc., (“Visus”) a clinical stage biopharmaceutical company focused on developing multi-targeted treatments for the eye, today announced it has expanded its ...